Day One Biopharmaceuticals, Inc. 8-K

What Happened
Day One Biopharmaceuticals (DAWN) filed an 8-K on March 2, 2026 to update its corporate presentation after Ipsen Pharma SAS received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. The CHMP recommended conditional marketing authorization of OJEMDA (tovorafenib) as monotherapy to treat children with relapsed or refractory BRAF‑altered pediatric low‑grade glioma. Day One previously entered an exclusive license agreement with Ipsen in July 2024 to commercialize OJEMDA outside the United States. The updated presentation is included as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: March 2, 2026 (Form 8-K, Item 7.01 Regulation FD disclosure).
• Regulatory milestone: CHMP issued a positive opinion recommending conditional marketing authorization for OJEMDA (tovorafenib) in the EU.
• Indication: monotherapy for children with relapsed or refractory BRAF‑altered pediatric low‑grade glioma.
• Corporate arrangement: Day One granted Ipsen an exclusive ex‑U.S. commercialization license in July 2024; updated corporate presentation attached as Exhibit 99.1.

Why It Matters
A CHMP positive opinion is a key regulatory milestone toward conditional approval in the European Union and advances the ex‑U.S. commercialization pathway for OJEMDA through Ipsen under the existing license. For investors, this represents progress on Day One’s regulatory and commercialization objectives for tovorafenib outside the U.S.; the filing does not include financial results, sales figures, or changes to guidance.